The estimated Net Worth of Roger L Pringle is at least $922 Tausend dollars as of 5 May 2017. Roger Pringle owns over 140,552 units of Orasure Technologies stock worth over $922,267 and over the last 21 years Roger sold OSUR stock worth over $0.
Roger has made over 4 trades of the Orasure Technologies stock since 2011, according to the Form 4 filled with the SEC. Most recently Roger exercised 140,552 units of OSUR stock worth $676,055 on 5 May 2017.
The largest trade Roger's ever made was exercising 140,552 units of Orasure Technologies stock on 5 May 2017 worth over $676,055. On average, Roger trades about 8,148 units every 84 days since 2004. As of 5 May 2017 Roger still owns at least 217,004 units of Orasure Technologies stock.
You can see the complete history of Roger Pringle stock trades at the bottom of the page.
Roger's mailing address filed with the SEC is 220 EAST FIRST STREET, , BETHLEHEM, PA, 18015.
Over the last 21 years, insiders at Orasure Technologies have traded over $21,897,384 worth of Orasure Technologies stock and bought 196,200 units worth $1,037,188 . The most active insiders traders include Douglas A Michels, Ronald H Spair und Michael J Gausling. On average, Orasure Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $221,123. The most recent stock trade was executed by Kathleen Gallagher Weber on 19 December 2023, trading 24,129 units of OSUR stock currently worth $194,238.
based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo
Orasure Technologies executives and other stock owners filed with the SEC include: